Table 4.

Nonhematologic adverse events observed in at least 3% of patients

ParameterN (%)
Decitabine (n = 73)Azacitidine (n = 40)
All GradesGrade 3All GradesGrade 3
Nausea11 (15)06 (15)0
Fatigue6 (8)04 (10)0
Infection/Neutropenic fever5 (7)4 (5)2 (5)0
Constipation3 (4)06 (15)0
Diarrhea2 (3)03 (8)0